Accessibility StatementSkip Navigation HAUPPAUGE, N.Y., Sept. 29, 2025 /PRNewswire/ -- Minicarm.com, a leading provider of imaging solutions for orthopedic and surgical practices, is proud to announce that it has secured an allocation of the Hologic Fluoroscan® Insightâ"¢ FD Mini C-Arm for resale in the United States. As Hologic transitions away from commercial activities related to the Fluoroscan Insight product line, Minicarm.com will continue to offer sales support for the remaining inventory, ensuring ...

Core Insights - VolitionRx Limited has signed a co-marketing agreement with Hologic Diagenode to promote its Nu.Q Discover service, which focuses on epigenetic profiling for drug developers and scientists [1][3][4] Company Overview - VolitionRx is a multi-national epigenetics company dedicated to advancing the science of epigenetics, aiming to improve outcomes for patients through earlier detection and monitoring of diseases [12][13] - Hologic, a company with over $4 billion in revenue for 2024, specializes in medical technologies and has extensive experience in various disease areas, including oncology and immunology [5][10] Product and Market Potential - The Nu.Q Discover service offers state-of-the-art assays for rapid epigenetic profiling, with an estimated total addressable market of $200 million annually [4][7] - The partnership aims to expand customer access to Nu.Q Discover assays, potentially leading to Hologic becoming an exclusive provider of these services [3][4] Strategic Goals - The collaboration is expected to enhance the reach of Nu.Q Discover services, leveraging Hologic's established client base and international presence [5][6] - Both companies aim to create value for clients by identifying specific epigenetic signatures that can inform personalized medicine approaches [6]

Core Insights - Hologic is set to present new data on its AI-powered mammography technology at the upcoming EUSOBI conference [1] Company Summary - Hologic's advancements in AI technology for mammography aim to enhance breast cancer detection and improve patient outcomes [1]

Core Insights - Hologic's Skeletal Health division has shown significant growth, with sales increasing by 62.1% in Q3 of fiscal 2025 due to the ramp-up of Horizon DXA systems [1][9] - The company will discontinue the Fluoroscan Insight FD mini C-arm by September 30, 2025, due to its low gross margin and limited growth potential [2][9] - Hologic has revised its 2025 revenue guidance to a range of $4.081 billion to $4.091 billion, supported by strong Q3 performance and reduced tariff impacts [3][9] Hologic's Business Performance - The Diagnostics business is expected to benefit from strong underlying growth drivers, including BV and CV/TV molecular diagnostic assays [3] - Breast Health is anticipated to show modest growth in Q4, while Surgical revenues are expected to be strong due to favorable year-over-year comparisons [3] - Skeletal Health is projected to experience outsized growth in Q4, competing against a full quarter of DXA stop-ship from the previous year [3][4] Market Position and Competitors - Hologic's stock has increased by 11.2% over the past six months, contrasting with a 9.4% decline in the industry [7] - GE Healthcare has introduced the Voluson Performance series in women's health ultrasound, enhancing its portfolio with AI and automation [5] - Becton, Dickinson & Company has partnered with Henry Ford Health for pharmacy automation and has placed its 1,000th BD Rhapsody System at a UK hospital [6]

Core Insights - Hologic and Thermo Fisher Scientific are key players in the diagnostics market, each with distinct strengths and market focuses [1][2] Hologic Overview - Hologic specializes in molecular diagnostic assays for infectious diseases, particularly in women's health, with a market cap of $14.75 billion [1] - The company has seen strong growth in its Molecular Diagnostics segment, particularly with the BV, CV/TV assay, which has become its second-largest test globally since its launch in 2019 [3] - Hologic's Breast Health business is recovering, with expectations to return to growth by Q4 of fiscal 2025, aided by new leadership and innovations [4] - The company has a strong GYN Surgical portfolio and has expanded its fibroid treatment offerings through the acquisition of Gynesonics [5] - Hologic maintains a solid financial position with $1.88 billion in cash and short-term investments and a net leverage ratio of 0.6 [6] - The company has raised its full-year revenue guidance to $1.03-$1.04 billion and adjusted EPS to $1.09-$1.12, despite facing cost pressures from tariffs [7] Thermo Fisher Overview - Thermo Fisher, valued at $181.10 billion, offers a wide range of diagnostic products and services across various sectors, including healthcare and food safety [2] - The company is experiencing growth in its bioproduction and pharma services, supported by significant innovations and product launches [8] - Thermo Fisher's capital deployment strategy includes strategic acquisitions and shareholder returns, with recent acquisitions aimed at enhancing its bioproduction capabilities [11] - The company has projected revenues between $43.6 and $44.2 billion and adjusted EPS of $22.22-$22.84 for the full year, both raised from prior estimates [13] Performance Comparison - Over the last six months, Hologic's stock has increased by 4.2%, while Thermo Fisher's stock has decreased by 7.7% [9][16] - Hologic's shares are trading at a forward five-year P/E of 14.41X, compared to Thermo Fisher's P/E of 20.12X, indicating a more favorable valuation for Hologic [17] - Analysts project a year-over-year EPS growth of 3.7% for Hologic, while Thermo Fisher's EPS is expected to improve by 3% [19][21] Investment Outlook - Both companies exhibit strong fundamentals and financial stability, with Hologic showing resilience in its growth areas and Thermo Fisher focusing on innovation and market expansion [22]

Core Viewpoint - Blackstone (BX.US) has renewed interest in acquiring Hologic, which could become one of the largest healthcare privatization deals of the year [1] Group 1: Company Developments - Blackstone's stock rose nearly 3%, closing at $188.90 [1] - Hologic's CEO Steve MacMillan's compensation terms and the recent decline in Hologic's stock price may be motivating factors for the potential sale [1] Group 2: Transaction Insights - Blackstone and TPG are currently conducting due diligence on Hologic [1] - A transaction is not expected to be finalized within the next month [1]

Core Viewpoint - Blackstone (BX.US) has renewed interest in acquiring Hologic, which could become one of the largest healthcare privatization deals of the year [1] Group 1: Company Developments - Blackstone's stock rose nearly 3% to $188.90 following the news of the potential acquisition [1] - Hologic's CEO, Steve MacMillan, may be incentivized to sell due to his compensation terms and the recent decline in the company's stock price [1] Group 2: Transaction Insights - Blackstone and TPG are currently conducting due diligence on Hologic [1] - A transaction is not expected to be finalized within the next month [1]

Core Insights - Hologic's international expansion is a crucial aspect of its growth strategy, but it faces macroeconomic challenges, particularly in China and Africa [1][8] - The Diagnostics segment is under pressure, but international markets are expected to contribute significantly to growth through 2026 and beyond [1] - The GYN Surgical segment is experiencing strong growth, particularly in international markets, with a nearly 25% increase in Q3 2025 [2][8] International Business Performance - Hologic's international business is projected to grow at a 4.7% CAGR from fiscal 2025 to 2027 [4] - The NovaSure product has shown consistent double-digit growth overseas, indicating strong potential for women's health advancements globally [2] - The Panther platform and Genius digital diagnostics system are achieving record utilization and positive feedback, respectively [3][8] Competitive Landscape - Abbott's international sales increased by 6.6% in Q2 2025, highlighting competitive dynamics in the market [5] - Thermo Fisher Scientific has launched new products targeting neurodegenerative disease research, indicating ongoing innovation in the industry [6] Stock Performance and Valuation - Hologic shares have declined by 18.2% over the past year, slightly better than the industry's decline of 18.4% [7] - The stock is trading at a forward three-year price-to-sales ratio of 3.57X, below the industry average of 3.96X, suggesting potential value [9]

Company Overview - Hologic (HOLX) shares increased by 7.7% to $68.2 in the last trading session, following a period of 6.6% loss over the past four weeks, indicating a significant rebound in investor sentiment [1][2] - The rise in Hologic's stock price is attributed to renewed interest from private equity firms Blackstone and TPG in acquiring the company, which could lead to one of the largest healthcare take-private transactions of the year [2] Earnings Expectations - Hologic is expected to report quarterly earnings of $1.10 per share, reflecting an 8.9% year-over-year increase, with revenues projected at $1.03 billion, a 4.6% increase from the previous year [3] - Despite positive earnings and revenue growth expectations, the consensus EPS estimate for Hologic has been revised marginally lower over the last 30 days, which may indicate potential challenges for price appreciation [4] Industry Context - Hologic operates within the Zacks Medical - Instruments industry, where another company, Alcon (ALC), has seen a decline of 0.6% to $77.2, with a return of -13.9% over the past month [4] - Alcon's consensus EPS estimate has decreased by 3.8% to $0.77, representing a year-over-year change of -4.9%, and it also holds a Zacks Rank of 3 (Hold) [5]

Federal Reserve Actions and Market Response - The Federal Reserve announced a 25-basis-point reduction in its benchmark interest rate, setting the new target range at 4% to 4.25% [2][8] - Following the announcement, the S&P 500 closed down 0.1%, while the Nasdaq saw a 0.3% decline; the Dow Jones Industrial Average closed up 0.5% at 45,984.88 [2][8] - The U.S. dollar rose for the seventh consecutive Fed day, defying typical post-cut trends [2] Tech Giants Eyeing New Horizons and Geopolitical Headwinds - Apple is reportedly exploring test production of foldable iPhones in Taiwan, targeting a 10% increase in total phone shipments in 2026, with a preliminary goal of producing approximately 95 million units [4][8] - Nvidia's CEO expressed disappointment over reports that China's internet regulator ordered major firms to halt purchases of Nvidia's AI chips, acknowledging geopolitical pressures [5][8] M&A and Corporate Strategy Shifts - Private equity firms Blackstone and TPG have renewed interest in acquiring medical device manufacturer Hologic, with a joint, non-binding offer exceeding $16 billion, although it was initially rejected [7][8] - Morgan Stanley announced the formation of a new Global Power and Energy Group, combining its Global Energy and Global Power and Utilities investment banking teams to adapt to evolving energy market dynamics [9][8] Global Trade and Geopolitical Developments - Mexico has initiated a public consultation process in anticipation of the 2026 review of the USMCA trade agreement, inviting input from economic sectors and stakeholders [10]